Hypothesis

Age-related loss of the mitochondrial-derived peptide SHLP2 does not merely reflect cumulative mtDNA damage; instead, it acts as a rheostat that sets a critical threshold for nuclear NAD+-dependent sirtuin (SIRT1/6) activity. When SHLP2 falls below a tissue‑specific threshold, NAD+ salvage is insufficient to sustain SIRT1/6 deacetylase function, leading to a bistable switch: (1) rapid accumulation of acetyl‑lysine marks on histones and nuclear proteins, (2) global epigenetic drift, and (3) activation of the inflammatory SASP. Restoring SHLP2 above the threshold re‑engages SIRT1/6 activity, but only when NAD+ levels are adequate, predicting a synergistic requirement for both SHLP2 supplementation and NAD+ boosting to reverse age‑associated epigenetic decline.

Mechanistic Model

1. SHLP2 signaling – SHLP2, encoded in the mitochondrial 16S rRNA region, is secreted and binds a putative mitochondrial inner‑membrane receptor that stimulates NAMPT activity, boosting NAD+ synthesis [https://www.jci.org/articles/view/158449].
2. NAD+‑sirtuin axis – NAD+ fuels SIRT1 and SIRT6 deacetylases, which remove acetyl groups from H3K9ac, H3K56ac, and NF‑κB p65, maintaining heterochromatin and suppressing SASP [https://www.jci.org/articles/view/120842].
3. Bistable switch – Mathematical modeling of the SHLP2→NAD+→SIRT1/6 circuit predicts two stable states: a "youthful" state (high SHLP2, NAD+, SIRT activity; low acetyl‑lysine) and an "aged" state (low SHLP2, NAD+, SIRT activity; high acetyl‑lysine). The transition occurs when SHLP2 drops below a critical heteroplasmy‑independent threshold (~30% of youthful levels), a point at which compensatory NAD+ salvage cannot keep pace with consumption.
4. Feedback to mitochondria – Loss of SIRT1/6 activity increases mitochondrial ROS via hyperacetylation of SOD2 and complex I subunits, further suppressing SHLP2 translation, creating a vicious loop.

Testable Predictions

• Prediction 1: In aged mice (≥24 mo), tissues with the steepest SHLP2 decline (e.g., muscle, brain) will show a sharp increase in H3K9ac and H3K56ac coinciding with SIRT1/6 activity loss, whereas younger mice will not.
• Prediction 2: Exogenous SHLP2 administration alone will modestly raise NAD+ and SIRT activity only in young mice; in aged mice, NAD+ will remain low unless combined with an NAD+ precursor (e.g., NR or NMN).
• Prediction 3: Combined SHLP2 + NAD+ booster treatment will restore SIRT1/6 deacetylase activity, reduce H3K9ac/K56ac, lower SASP cytokines (IL‑6, TNF‑α), and improve stem cell function more than either intervention alone.
• Prediction 4: Genetic ablation of the putative SHLP2 receptor (to be identified via affinity‑purification mass spectrometry) will phenocopy aging: premature NAD+ drop, SIRT loss, and epigenetic drift, even in young animals.

Experimental Design

1. Measure SHLP2, NAD+, SIRT activity, and acetyl‑lysine in young (3 mo) vs aged (24 mo) C57BL/6 mice across muscle, brain, and intestinal crypts (n=5 per group). Use ELISA for SHLP2, enzymatic cycling assay for NAD+, fluorometric deacetylase kits for SIRT1/6, and Western blot with acetyl‑lysine antibodies.
2. Intervention groups (aged mice): vehicle, SHLP2 (2 mg/kg i.p. 3×/wk), NAD+ booster (NMN 400 mg/kg/day oral), SHLP2 + NMN. Treat for 8 weeks.
3. Readouts: (a) NAD+ and SIRT activity; (b) global H3K9ac/H3K56ac via quantitative mass spectrometry; (c) SASP cytokine panel; (d) intestinal stem cell colony‑forming units and myeloid bias assays.
4. Receptor identification: biotinylated SHLP2 pull‑down from mitochondrial lysates followed by LC‑MS/MS; validate candidate via CRISPR knockout in myeloid progenitors.
5. Falsifiability: If SHLP2 loss does not correlate with a threshold‑dependent drop in NAD+/SIRT activity, or if combined SHLP2 + NMN fails to outperform monotherapies in improving epigenetic and SASP markers, the hypothesis is refuted.

Significance

This hypothesis reframes mtDNA‑derived peptides not as passive damage markers but as active regulators of a nuclear NAD+‑sirtuin rheostat. It suggests that successful anti‑aging strategies must coordinate mitochondrial signaling (SHLP2) with nuclear cofactor availability (NAD+), moving beyond isolated genome editing toward integrated mito‑nuclear therapeutics.